Affordable Access

Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells.

Authors
  • Gaschott, T
  • Maassen, C U
  • Stein, J
Type
Published Article
Journal
Anticancer research
Publication Date
Jan 01, 2001
Volume
21
Issue
4A
Pages
2815–2819
Identifiers
PMID: 11724360
Source
Medline
License
Unknown

Abstract

Our data may provide a rationale for the therapeutic use of peroral tributyrin in patients with pancreatic cancer, because this drug enables plasma concentrations of butyrate which inhibit growth, induce differentiation and cause apoptosis in pancreatic cancer cells.

Report this publication

Statistics

Seen <100 times